Ann: Dermatology Asset Acquired to Accelerate Path to Revenue, page-26

Competition to this is from Qbrexza Also recently approved in Japan, but an article from US suggests Ecclock is suprior!!.........Reading attached for those interested, I cut and paste the paragraph that hit me...

Also interesting reading about Journey medical, similar to BOT

Journey Medical Corporation’s Qbrexza (glycopyrronium tosylate), a topical anticholinergic drug, was approved by the FDA in 2018 and has become a game-changer in the AH treatment paradigm. Before Qbrexza’s approval, antiperspirants were the only choice of therapy. Qbrexza wipes are easy to use with few side effects, resulting in rapid acceptance of the medication by patients and improved adherence. Currently, Brickell Biotech’s Ecclock (sofpironium bromide) is the only anticholinergic pipeline agent in Phase III development. Despite having superior efficacy to Qbrexza, Ecclock gel does not offer a better delivery method, particularly one that minimizes hand contact with the drug. This is a major opportunity remaining for drug developers in this space.

https://www.pharmaceutical-technology.com/comment/unmet-needs-axillary-hyperhidrosis/

https://www.globenewswire.com/news-release/2022/02/11/2383682/0/en/QBREXZA-Rapifort-Wipes-2-5-Receives-Manufacturing-and-Marketing-Approval-in-Japan-Triggering-2-5-Million-Milestone-Payment-to-Journey-Medical-Corporation.html

https://journeymedicalcorp.com/our-brands/